#27 When drugs damage the liver – Rita Baião

The liver is the primary site for drug metabolism in the body,
but it can be severely damaged by medicines or their toxic
compounds. Rita Baião from the North Lisbon University Hospital
Center reviews what pharmacovigilance professionals should know
about drug-induced liver injury (DILI).

Tune in to find out:


Who is most at risk of developing DILI

How to diagnose the condition and control the damage

How to assess case reports of DILI



Want to know more?


This infographic in Nature Reviews nicely summarises the
mechanisms, diagnosis, and management of drug-induced liver
injury.

In this report, the Council for International Organizations
of Medical Sciences provides a global perspective on DILI
detection, susceptibility factors, outcomes, and more.

In this Drug Safety article, industry representatives outline
how to identify, mitigate, and communicate the risk of DILI
during drug development. 

The PRO-EURO DILI NETWORK coordinates research efforts on
DILI across Europe and provides a forum to exchange knowledge and
training on the topic. Similar initiatives include the Spanish
DILI Registry and the Latin American DILI Network.

The free online tool LiverTox contains up-to-date information
on drug-induced liver injury for medicines and herbal products.



To learn more about post-marketing surveillance and clinical care
of DILI, check out Uppsala Monitoring Centre’s free online course
on the topic.

For more on the clustering algorithm vigiGroup, revisit this
interview with UMC scientists Jim Barrett and Joe Mitchell.





Join the conversation on social mediaFollow us on
Facebook, LinkedIn, X, or Bluesky and share your thoughts about
the show with the hashtag #DrugSafetyMatters.

Got a story to share?We’re always looking for new
content and interesting people to interview. If you have a great
idea for a show, get in touch!

About UMCRead more about Uppsala Monitoring Centre
and how we work to advance medicines safety.